NIS2 cybersecurity in pharma is an operational resilience requirement, not a stand-alone IT project. A cyber incident can stop a filling line, isolate a laboratory, interrupt a cold chain, corrupt a clinical dataset or make a validated system unavailable. Each outcome can affect product quality, patient safety and continuity of supply.
Directive (EU) 2022/2555, known as NIS2, creates a common EU baseline for cybersecurity risk management, management oversight and significant-incident reporting. The legal duty is implemented through national law. A company must therefore read the Directive together with the rules, thresholds, registration procedures and competent-authority guidance in every Member State where it falls within scope.
This guide converts the legal baseline into actions and evidence for pharmaceutical manufacturers, biotechnology companies, medicinal-product R&D organisations, contract manufacturing organisations (CMOs), contract research organisations (CROs) and their critical suppliers. It also explains where NIS2 must be aligned with GxP, Computerized System Validation (CSV), Computer Software Assurance (CSA), GAMP 5 and existing quality-management processes.
This article covers pharma-specific implementation. For the detailed evidence model, see the TTMS NIS2 compliance documentation and evidence checklist.
1. Why pharmaceutical operations are a priority cyber target under NIS2
NIS2 places the manufacture of basic pharmaceutical products and pharmaceutical preparations within the health sector in Annex I, alongside healthcare providers, EU reference laboratories and entities carrying out research and development of medicinal products. That classification reflects systemic impact: disruption can affect access to medicines and public-health response, not only one company’s balance sheet.
The threat picture supports that treatment. ENISA reported that, among health-related incidents analysed for its 2024 threat landscape, 45% involved ransomware and 28% involved data breaches. A separate commercial dataset counted 4,198 ransomware cases exposed on dark-web leak sites across all sectors in the first half of 2025, 49% more than in the comparable 2024 dataset. The 4,198 figure is not pharma-specific, so it should not be presented as a count of attacks on pharmaceutical or biotechnology organisations.
Pharma combines assets that create leverage for attackers: intellectual property, clinical and patient-related data, regulated production, scarce batches, time-sensitive logistics and a broad supplier network. The same identity platform, integration layer or remote-maintenance channel may connect corporate IT with ERP, MES, LIMS, ELN, EDC and operational technology (OT). An attacker does not need to compromise every system. Disrupting one shared dependency may be enough to stop release, testing or distribution.
Treat the business impact as a chain. Map each critical product or service to facilities, processes, systems, data, utilities, people and third parties. Record the maximum tolerable outage and the quality consequences of data loss or delayed review. That service map becomes evidence for risk analysis, business continuity, recovery priorities and supply-chain decisions.
2. NIS2 in life sciences: scope, classification and legal status
NIS2 expanded the EU cybersecurity baseline beyond the narrower NIS1 model. It applies, as a rule, to medium-sized and large entities of a type listed in Annex I or Annex II, subject to specific inclusions and exceptions. In life sciences, the legal analysis must start with what the entity actually does—not the brand description “pharma”, “biotech” or “healthcare”.
Activities may include medicinal-product R&D, API or finished-product manufacture, device manufacture, clinical operations, distribution, marketing, digital services or combinations of them. A group can contain entities with different statuses. A CMO or CRO is not automatically in or out merely because of its label. The relevant activity, size, establishment, jurisdiction and any national designation must be documented.
2.1 From NIS1 to NIS2: what changed for health and pharma
NIS2 widens sector coverage, standardises a minimum set of cybersecurity risk-management measures, sets a staged significant-incident reporting model and strengthens supervision and enforcement. It requires management bodies to approve risk-management measures, oversee implementation and receive training. It also requires Member States to maintain national cybersecurity strategies and incident-response structures.
The result is a common baseline, not identical administration across the EU. Registration, thresholds, forms, competent authorities, language, audit expectations and sanctions are implemented nationally. In July 2026, the Commission referred Ireland, Spain, France and the Netherlands to the Court of Justice for failing to notify full transposition. Cross-border groups still need a jurisdiction register and local legal verification.
Existing GMP and quality-management governance can provide a starting structure. Management review, change control, deviation management, CAPA, supplier qualification, training and periodic review already create owners and records. Extend those processes to cybersecurity; do not assume that GxP evidence automatically proves NIS2 compliance.
2.2 Essential or important entity? Classify before selecting controls
Under Article 3, an Annex I entity that exceeds the ceiling for a medium-sized enterprise is generally an essential entity. Other medium-sized entities within Annex I or Annex II are generally important entities, unless a specific rule or national designation changes the result. Certain entity types are essential regardless of size. Micro and small enterprises are generally excluded, but Article 2 contains exceptions based on criticality and other factors.
Pure distribution or marketing activity may fall outside the listed pharma categories when the entity performs no covered activity and is not designated on another basis. Conversely, an organisation conducting medicinal-product R&D can fall within Annex I even if it does not manufacture. Medical-device coverage also requires careful reading of the relevant Annex category; not every device business has the same classification.
Create a signed scope memorandum for each legal entity. Include activities, NACE or equivalent classification, headcount and financial data, establishments, services, national rules, group dependencies and the reason for the conclusion. Record who approved it and when it must be reviewed. This memorandum is the first auditable artefact; a product brochure or a group-level assumption is not enough.
3. Four compliance pillars for pharmaceutical organisations
Organise NIS2 around four connected pillars: risk management, significant-incident reporting, management accountability and supply-chain security. Each needs an owner, a procedure and operating evidence.
3.1 Article 21 risk management: ten minimum areas
Article 21 requires appropriate and proportionate technical, operational and organisational measures based on an all-hazards approach. The ten minimum areas below should be mapped to services and risks, not treated as a generic tool-purchasing list.
Article 21 area
Pharma implementation focus
Typical audit evidence
1. Risk analysis and information-system security policies
Link product, patient and service impact to IT, OT and GxP systems
Approved method, service map, risk register, treatment decisions
2. Incident handling
Coordinate security, quality, privacy, legal, production and communications
Incident plan, severity matrix, case records, after-action reports
3. Business continuity, backup, disaster recovery and crisis management
Prioritise batch, laboratory, release and cold-chain dependencies
BIA, RTO/RPO, recovery plans, restore tests, exercise reports
4. Supply-chain security
Assess API, CMO, CRO, logistics, cloud and maintenance dependencies
Supplier tiering, due diligence, contracts, monitoring, exit plans
5. Secure acquisition, development and maintenance, including vulnerability handling and disclosure
Connect security changes to validated-state and change-control decisions
Security requirements, threat models, vulnerability records, change packages
6. Assessment of control effectiveness
Test design, coverage and operating results
Control tests, metrics, internal audits, CAPA and closure evidence
7. Cyber hygiene and training
Train by role, including engineers, laboratory staff and management
Curricula, attendance, competence checks, phishing or exercise results
8. Cryptography and encryption
Protect data and communications while managing keys and certificates
Cryptography standard, key inventory, certificate monitoring, exceptions
9. HR security, access control and asset management
Control joiners, movers, leavers, privileged access and system ownership
Asset register, access reviews, PAM records, segregation-of-duties evidence
10. MFA or continuous authentication and secure communications
Cover remote access, privileged actions and exposed services based on risk
MFA coverage, exception register, secure-channel configuration and reviews
Build requirements traceability between each NIS2 measure, the service risk, the control, the system owner and the evidence source. Existing GxP processes can carry part of the load. Vulnerability remediation can use change control; control testing can align with periodic review and CSA; security training can use the controlled learning system. The mapping must also expose gaps. A validated application with no tested recovery process remains a continuity risk.
3.2 Article 23 reporting: 24 hours, 72 hours and one month
For a significant incident, Article 23 establishes staged reporting: an early warning without undue delay and within 24 hours after becoming aware; an incident notification without undue delay and within 72 hours; and a final report no later than one month after the incident notification. Intermediate or progress reports may also be required. If the incident is ongoing at the one-month point, a progress report replaces the final report and the final report follows within one month after handling ends.
The clock starts from awareness, not from completion of a forensic investigation. Define who can declare awareness, who assesses significance, who contacts the national CSIRT or competent authority and who coordinates parallel duties under GDPR, sector rules, contracts and, where relevant, medical-device obligations. Preserve both the decision to report and a reasoned decision not to report.
Real-time visibility across identity, network, endpoint, cloud, ERP, MES, LIMS, ELN, EDC and OT improves the chance of meeting the timetable. A central SIEM can support detection and chronology, but it does not make a legal significance assessment. Use a human-in-the-loop process with on-call authority, a current contact list, pre-approved templates and a decision log.
In validated environments, deploy monitoring through approved change control. Passive OT monitoring, network telemetry and controlled log forwarding may reduce interference with production assets. Test the entire route in a tabletop exercise: alert, technical triage, quality impact, legal assessment, management escalation, authority submission and follow-up.
3.3 Article 20: management responsibility and board-level evidence
Management bodies must approve the Article 21 measures, oversee implementation and can be held liable for infringements under national law. Members must follow training, and Member States must encourage regular training for employees. Evidence should show informed oversight, not a ceremonial annual presentation.
Provide the board with decisions it can act on: top service risks, overdue high-risk treatments, control effectiveness, significant incidents, recovery-test failures, critical supplier exposure, material exceptions and required investment. Retain agendas, papers, minutes, approvals, challenge and follow-up. Record training content, attendance and an effectiveness check.
The Directive also allows competent authorities, in specified circumstances concerning essential entities, to request temporary suspension of a certification or authorisation and a temporary prohibition on certain senior managers exercising managerial functions until deficiencies are remedied. This is a supervisory measure with conditions, not an automatic personal ban after every incident. Avoid overstating it as criminal liability.
3.4 Article 21(2)(d): API, CMO, CRO and logistics risk
Map suppliers to the services and products they can affect. Include API and excipient suppliers, CMOs, CROs, testing laboratories, packaging, cold-chain logistics, cloud platforms, managed services, equipment vendors, remote maintenance and single-source technology dependencies.
Tier suppliers using impact, access, substitutability, concentration and recovery time. Due diligence should test the evidence relevant to the service: control scope, incident history, privileged access, subcontractors, vulnerability handling, backup and recovery, secure development, geographic concentration and exit feasibility. A questionnaire is a declaration; a certificate has value only after its scope, exclusions and period are checked.
Contracts should define minimum controls, incident-notification timing, cooperation, audit or assurance rights, vulnerability handling, subcontractor conditions, data return, continuity and exit. Contract language does not replace monitoring. Record reviews, adverse findings, risk acceptance, compensating controls, owners and expiry dates.
4. Pharma-specific cybersecurity challenges NIS2 does not solve by itself
NIS2 states outcomes and minimum risk areas. It does not prescribe how to patch a validated MES, monitor a PLC in a clean manufacturing area or preserve ALCOA+ principles during a cyber response. These decisions require security, quality, engineering and regulatory roles to work from one risk record.
4.1 Secure validated systems without losing validated state
A security patch or configuration change can affect the validated state of MES, LIMS, QMS, chromatography, environmental-monitoring or other GxP systems. Delaying every patch is unsafe; applying every patch without assessment is also unsafe. The control objective is a documented, risk-based decision.
Connect vulnerability management to change control. Record asset and version, vulnerability severity, exploitability, patient or product impact, exposure, vendor support, proposed change, test scope, rollback, compensating controls and approval. Use GAMP 5 and CSV or CSA principles to scale assurance to the risk of the changed function. Re-test what can affect intended use, data integrity, electronic records, interfaces and critical calculations.
Maintain validated state throughout the lifecycle. Periodic review should reconcile configuration, deviations, patches, access, backup, audit trails, incidents and supplier changes. Emergency changes need predefined authority and retrospective quality review. Evidence should make the sequence traceable from threat to decision, test, release and post-implementation monitoring.
4.2 Protect clinical-trial data, IP and patient-related information
NIS2 covers entities carrying out R&D activities of medicinal products when the scope and size rules are met. Their risk model must protect availability, authenticity, integrity and confidentiality across protocol design, investigator sites, eCOA, EDC, safety systems, biostatistics, regulatory submissions and partner exchanges.
Apply ALCOA+ data-integrity thinking: records should remain attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available. Cyber controls must protect the audit trail and the context required to interpret data. Detect bulk data exports, unusual privileged activity, manipulation and unauthorised interface changes. Test restoration of both data and metadata.
Privacy belongs in a coordinated but distinct assessment. A single event can create a NIS2 significant-incident question and a GDPR personal-data-breach question with different tests, recipients and deadlines. Maintain one fact base and timeline, then run separate legal decision paths.
4.3 IT/OT convergence in manufacturing and clean areas
OT assets often have long lifecycles, vendor constraints, deterministic communications and limited maintenance windows. Standard endpoint agents may be unsupported. A production pause can itself create quality and supply consequences. Treat OT as a distinct engineering risk domain connected to enterprise governance.
Begin with passive discovery and verified ownership. Define zones and conduits, restrict remote access, separate safety and control functions from business networks, protect engineering workstations, monitor allowed communications and control removable media. Use compensating controls when patching is not feasible. Confirm that segmentation and fail-safe behaviour do not disrupt real-time control or environmental conditions.
Every change should have cyber, automation and quality acceptance criteria. Test during approved windows, document rollback and retain configuration baselines. The evidence package should include current diagrams, firewall rules, remote-access reviews, alert handling, backup or configuration-restore tests and approved exceptions.
5. NIS2, GDPR, MDR and quality systems: one management model
NIS2 protects the resilience and security of network and information systems. GDPR protects personal data and creates breach-notification duties. MDR and IVDR govern medical devices and include safety, quality and post-market obligations. GMP and GxP govern product quality and data integrity. One incident can activate several regimes, but the legal tests are not interchangeable.
Build one management model with multiple compliance mappings. Use a common service catalogue, asset register, risk method, incident record, supplier register, training process, CAPA workflow and evidence index. Map each control to the applicable NIS2 article, national law, GDPR requirement, quality procedure and device obligation. This reduces duplicate evidence without collapsing distinct decisions.
Create a regulatory decision matrix before an incident occurs. For each regime, record the trigger, decision owner, recipient, deadline, minimum content and rule for follow-up. Add contractual notifications and communications to investigators, insurers, partners and affected customers. During an incident, one coordination lead should maintain the verified facts, while qualified owners make the separate legal and quality decisions. This model reduces contradictory reporting without allowing the shortest deadline to erase the distinct tests applied by each regime.
ISO/IEC 27001 can provide a useful information-security management structure; it does not by itself prove NIS2 scope, registration or national reporting compliance. ISO/IEC 42001 can support governance where AI is used in LIMS analytics, quality review or security operations, but AI controls still require validation, data-integrity assessment and human oversight appropriate to the use case.
Design an integrated incident form with separate sections for service impact, product and patient impact, personal data, regulatory status, notification decisions and communications. The same verified timeline can support the CSIRT, data-protection authority, quality unit and management without creating contradictory versions.
6. Penalties and enforcement: the cost of non-compliance
Article 34 requires Member States to provide maximum administrative fines for essential entities of at least EUR 10 million or at least 2% of worldwide annual turnover in the preceding financial year, whichever is higher. For important entities, the corresponding levels are at least EUR 7 million or 1.4%, whichever is higher. National law determines the applicable enforcement process and may set higher maximums or additional measures.
Fines are only one exposure. A cyber incident can generate lost sales, scrapped batches, delayed trials, recovery costs, contractual claims, privacy consequences and loss of confidence. Merck reported that its 2017 network attack disrupted manufacturing, research and sales, reduced 2017 sales by approximately USD 260 million and generated USD 285 million of manufacturing and remediation expense net of stated insurance recoveries; residual backlog affected 2018 sales by approximately USD 150 million.
Do not justify controls only by comparing programme cost with the statutory maximum. Prioritise by service impact, credible threat, control weakness and legal duty. The board should see both compliance exposure and the operational loss scenario for each critical product or service.
7. A 9-12 month NIS2 implementation roadmap for pharma
A 9-12 month programme can organise remediation, but it is not a legal grace period. Organisations already subject to national implementing law must meet current duties while improving maturity. Sequence work around critical risk and approved change windows in validated environments.
7.1 Step 1: scope and gap analysis
Confirm each legal entity’s status and jurisdiction. Inventory critical services and products, then map IT, OT, laboratory, clinical, data, facility, people and supplier dependencies. Assess the ten Article 21 areas and national obligations.
The assessment should produce an approved scope memorandum, jurisdiction register, service and dependency map, asset baseline, gap report, risk-ranked remediation plan and evidence index. Escalate any unknown externally exposed asset or unsupported critical system immediately.
7.2 Step 2: governance and accountability
Assign executive sponsorship, service owners, control owners and an incident-reporting authority. Define RACI across security, IT, OT, engineering, quality, privacy, legal, procurement, HR, communications and business continuity.
At this stage, the organisation should have a governance charter, RACI, management reporting pack, risk-acceptance thresholds, training plan, CSIRT contact matrix and defined authority for isolating production or laboratory systems.
7.3 Step 3: technical and organisational controls
Prioritise identity, privileged access, MFA, network segmentation, secure remote access, EDR where supported, passive OT monitoring, central logging, vulnerability management, protected backups and recovery. Connect each change to quality and validation procedures.
Completion is evidenced by approved architectures, control requirements, implementation records, validation or assurance evidence, coverage metrics, an exception register and tested rollback. Measure the population covered, not only whether a tool was purchased.
7.4 Step 4: supplier verification and continuous monitoring
Tier API, CMO, CRO, laboratory, logistics, cloud, software and maintenance suppliers. Run due diligence proportional to access and impact. Remediate contracts and establish monitoring triggers.
The operational output is a maintained supplier register supported by a criticality model, evidence reviews, risk decisions, security clauses, incident contacts, a monitoring schedule, concentration analysis and exit plans. Reassess after a material change or incident.
7.5 Step 5: build and test incident response
Create playbooks for ransomware, data exfiltration, validated-system compromise, OT disruption, supplier incident and loss of a critical cloud service. Include quality and regulatory decisions, not only technical containment.
The response capability should be documented in an incident plan, 24/72-hour and final-report templates, a significance assessment, an evidence-preservation method and a tabletop report. Run the exercise with executives and on-call personnel. Track corrective actions to verified closure.
7.6 Step 6: document, audit and sustain
Convert control operation into evidence by design. Automate controlled reports where practical, identify record owners and set retention based on national law, sector duties, investigation needs and risk. Review the programme after incidents, major changes and legal updates.
The programme closes with a controlled policy set, evidence index, management minutes, training records, incident and supplier files, recovery-test results, effectiveness testing, an internal-audit report and a CAPA register. Independent review should confirm closure of high-risk findings.
8. Documented cyber incidents: practical NIS2 lessons
Public incident reports rarely prove which internal control failed. Use them to test plausible scenarios, not to accuse an organisation of a control deficiency that has not been established.
Merck’s 2017 attack demonstrates that enterprise malware can reach manufacturing, research, sales and fulfilment at the same time. The NIS2 lesson is to map shared dependencies, segment environments, protect recovery capabilities and quantify product-level continuity. Exercise the decision to isolate a plant system when isolation may interrupt production.
The 2020 cyberattack on the European Medicines Agency unlawfully accessed documents related to COVID-19 medicines and vaccines. EMA reported that some leaked material, including correspondence, had been manipulated before publication. The lesson is broader than confidentiality: protect authenticity, integrity and provenance across regulator and partner exchanges, and prepare communications for manipulated or incomplete data.
Cencora disclosed in February 2024 that data had been exfiltrated from its information systems and might contain personal information. It stated at the time that operations remained functional and that containment, investigation, law-enforcement engagement and external support had begun. The lesson is to maintain rapid cross-functional triage even when availability is not affected: exfiltration can still trigger NIS2, privacy, contractual and trust decisions.
For each scenario, retain the alert timeline, affected services, evidence sources, quality assessment, reporting decision, management escalation and corrective actions. Link lessons to Article 21 controls and test whether the same evidence could support the 24-hour early warning.
9. Selecting expert support for NIS2 implementation
A pharma NIS2 partner must combine cybersecurity, regulated quality and implementation capability. Ask for evidence that the team can classify scope, map services, design IT/OT controls, manage validated change, build CSV or CSA evidence, assess suppliers, run incident exercises and explain residual risk to management.
Evaluate the delivery model. A one-time gap report does not sustain compliance. Managed services can operate monitoring, vulnerability triage, evidence collection and supplier review, but accountability remains with the regulated organisation and its management. Define ownership, escalation, service levels, evidence access and exit from the start.
Request sample deliverables before selection: a redacted scope memorandum, an Article 21 traceability matrix, a validated change package, an OT risk assessment, a supplier finding and an executive incident exercise report. Check whether conclusions identify assumptions, evidence and residual risk. Confirm that security specialists can work with quality, automation and legal teams, and that records can be transferred into the organisation’s controlled repositories. The partner should leave the organisation with an operating process and usable evidence, not a slide deck that cannot be maintained.
TTMS combines an ISO/IEC 27001 information-security management environment with pharmaceutical computerized-system validation services aligned to GAMP 5 and Annex 11. Its published quality offering covers CSV and CSA across the system lifecycle. In February 2026, TTMS reported becoming the first Polish company to obtain accredited ISO/IEC 42001 certification for its AI management system after an audit by TÜV Nord Poland. These credentials are relevant where cyber controls, validated systems and governed AI must remain auditable in one operating model.
To arrange a scoping call focused on legal entities, regulated services, critical products, validated systems, OT dependencies and current evidence, contact TTMS. The first output should be a defensible scope and prioritised action plan—not a generic control catalogue.
10. Frequently asked questions about NIS2 cybersecurity in pharma
Does NIS2 apply to every pharmaceutical company?
No. Scope depends on activity, size, establishment, national law and designation. Manufacturing and medicinal-product R&D are listed; marketing or distribution alone may lead to a different result. Document the conclusion for each legal entity.
Is every pharmaceutical manufacturer an essential entity?
No. Annex I classification does not automatically make every manufacturer essential. Size thresholds, Article 3 rules, exceptions and national decisions determine whether an organisation is essential, important or outside scope. Group companies may reach different conclusions.
What are the main NIS2 incident-reporting deadlines?
For a significant incident, the Directive sets an early warning within 24 hours of awareness, an incident notification within 72 hours and a final report within one month. National procedures and parallel duties under GDPR or sector rules must also be checked.
How do NIS2, GxP and Annex 11 interact in pharmaceutical environments?
NIS2 governs cyber risk and resilience; GxP and Annex 11 govern product quality, data integrity and computerized systems. Use one risk and change-control model while preserving separate legal assessments and validation evidence for security changes.
How should security patches be handled in validated GxP systems?
Route the vulnerability through risk assessment and controlled change. Document exploitability, product or patient impact, test scope, rollback and compensating controls. Apply CSV or CSA assurance proportionate to the affected function and retain traceability from the vulnerability to approval and post-change review.
Read more
